HWM

Operationally, Howmet is exceptional. Revenue has compounded from $4.97B (FY2021) to $8.25B (FY2025), up 11.1% last year, while net income rose nearly six-fold over that span ($258M → $1.51B) and diluted EPS jumped 32% to $3.71. This is high-quality growth, not just volume: operating margin is 24.8% and net margin 18.3%, ROE is a standout 28.2%, and operating cash flow surged 45.1% to $1.88B against $453M of capex (~$1.4B free cash flow). The balance sheet is de-risking in parallel — long-term debt fell 13.6% to $2.86B, total debt dropped $265M to $3,050M per MD&A (early redemption of the 2027 Notes), equity grew 17.5%, and liabilities/equity sits at a comfortable 1.09x. Management returned $700M via buybacks. The MD&A confirms the engine of this: ~70% of revenue from commercial/defense aerospace, with growth in aero and gas turbines including engine spares, and pricing running ahead of material and inflationary cost pass-through. Segment Adjusted EBITDA rose 25% to $2,507M. By every fundamental lens this is a best-in-class industrial.

The problem is the price. At $277.66 the stock trades at 74.8x trailing EPS and 13.5x sales — a $111B market cap on $8.25B of revenue. Even crediting 32% EPS growth, that's a PEG near 2.3x and leaves no margin of safety. The shares closed at $205.02 on Dec 31, 2025 and are up roughly 35% in under six months; the filing itself notes a 1,453% gain since the 2020 Arconic separation. A multiple this rich requires flawless execution and a continued up-cycle to be sustained.